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Background:  Microvascular dysfunction due to embolization plays an important role on tissue injury in patients with STEMI, and thrombectomy 
and distal protection (DP) are performed to protect microcirculation against emboli. Nicorandil, a hybrid between a mitochondrial KATP-channel 
opener and NO, has shown to dilate coronary resistance vessel. We assessed the hypothesis that nicorandil can further improve microvascular 
function in patients with STEMI undergoing full course of anti-embolic device therapy.
Methods:  Consecutive 56 patients with STEMI were enrolled. All patients underwent thrombectomy followed by PCI using a distal protective device 
(FILTRAP). The patients were divided into two groups: nicorandil group (n=27) and control group (n=29). In the nicorandil group, nicorandil infusion 
was initiated before PCI (4 mg/h and 6 mg bolus immediately before stent implantation) and was continued for 24 hours. We compared the rate of 
final TIMI 3, corrected TIMI frame count, ST resolution and peak CK/CK-MB between the two groups.
Results:  The rates of final TIMI 3 were 100% (27/27) in the nicorandil group and 90% (26/29) in the control group (P=0.13). Final corrected 
TIMI frame count was lower in the nicorandil group than in the control group (10.4±4.3 vs. 14.4±9.0; P=0.040), and ST resolution (>50%) was 
significantly higher in the nicorandil group than in the control group (70% vs. 48%; P=0.048). There was no difference in peak CK-MB, LVEF 
and LV volumes at 6 months, and the incidence of MACE during follow-up (death, heart failure and revascularization) between the two groups. 
Hospitalization due to heart failure was not observed in the nicorandil group but in 3 patients of the control group (10%, P=0.13).
Conclusions:  Addition of nicorandil treatment to anti-embolic device therapy (thrombectomy and distal protection) can further improve 
microvascular function in patients with STEMI.
